| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 03/31/2009 | US7511068 antiinflammatory agents |
| 03/31/2009 | US7511061 Triazoles as farnesyl transferase inhibitors |
| 03/31/2009 | US7511053 Spiroazacyclic compounds as monoamine receptor modulators |
| 03/31/2009 | US7511047 Kinase inhibitors |
| 03/31/2009 | US7511031 Transcutaneous photodynamic therapy; patch placed over target tissue; liposomal, transdermal, iontophoretic photosensitizing agent; light emitting diodes; atherosclerotic lesions and restenotic lesions |
| 03/31/2009 | US7511027 Administering a nucleoside or a nucleoside analog, such as (5'-fluoro-5-methyl-beta-arabinofuranosyl-uridine) or salt or prodrug that suppresses the expression of hepatitis B surface or preS1 antigen in the host 100-fold |
| 03/31/2009 | US7511010 Pharmaceutical or cosmetic composition and use of a PKC inhibitor with an MMP inhibitor for inhibiting Langerhans' cell migration |
| 03/31/2009 | US7510870 STAT3 activated stem cell |
| 03/31/2009 | US7510853 Exhibiting similarity to cytokine; isolated or recombinant polynucleotide encoding antigenic polypeptide of sequence 2 |
| 03/31/2009 | US7510843 Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease |
| 03/31/2009 | US7510830 Cancer treatment by combination therapy |
| 03/31/2009 | US7510826 Process for the depletion or removal of endotoxins |
| 03/31/2009 | US7510702 Condensation aerosol for delivery of a drug selected from the group consisting of indomethacin, ketoprofen, celcoxib, rofecoxib, meclofenamic acid, fenoprofen, diflunisal, tolfenamic acid, naproxen, ibuprofen, flurbiprofen and nabumetone |
| 03/31/2009 | CA2448602C Pyrimidine, triazine and pyrazine derivatives as glutamate receptors |
| 03/31/2009 | CA2417897C Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| 03/31/2009 | CA2366256C Tropane analogs and methods for inhibition of monoamine transport |
| 03/31/2009 | CA2328368C Anti-inflammatory agents |
| 03/31/2009 | CA2307285C Agent for prophylaxis and treatment of glaucoma |
| 03/31/2009 | CA2292549C Use of colchinol derivatives as vascular damaging agents |
| 03/31/2009 | CA2192467C Calcium binding recombinant antibody against protein c |
| 03/31/2009 | CA2066204C Cystic fibrosis gene |
| 03/26/2009 | WO2009038695A1 Method of treating gaucher disease |
| 03/26/2009 | WO2009038157A1 2,3-dihydroiminoisoindole derivative |
| 03/26/2009 | WO2009038112A1 Solid preparation comprising npyy5 receptor antagonist |
| 03/26/2009 | WO2009038107A1 Combined pharmaceutical preparation for treatment of type-2 diabetes |
| 03/26/2009 | WO2009038106A1 Oral administration drug containing alanyltyrosine |
| 03/26/2009 | WO2009038089A1 Anti-fatigue agent comprising sesamin and vitamin-e |
| 03/26/2009 | WO2009038064A1 Heterocyclic derivative having inhibitory activity on type-i 11β-hydroxysteroid dehydrogenase |
| 03/26/2009 | WO2009038057A1 Nitrogenated fused-ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes |
| 03/26/2009 | WO2009038012A1 Heterocyclic compound |
| 03/26/2009 | WO2009037855A1 Oral and skin compositions |
| 03/26/2009 | WO2008074488A3 Construction and use of transfection enhancer elements |
| 03/26/2009 | US20090082713 Method of enhancing iontophoretic delivery of a peptide |
| 03/26/2009 | US20090082567 2,4-pyrimidinediamine compounds and their uses |
| 03/26/2009 | US20090082446 Use of Hydroxyoleic acid and related compounds in the manufacture of drugs |
| 03/26/2009 | US20090082424 Small molecule antagonists of bcl-2 family proteins |
| 03/26/2009 | US20090082416 Deuterium-enriched bendamustine |
| 03/26/2009 | US20090082406 Cancer Therapy |
| 03/26/2009 | US20090082390 Piperidine compounds for use as orexin receptor antagonist |
| 03/26/2009 | US20090082384 Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| 03/26/2009 | US20090082379 Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors |
| 03/26/2009 | US20090082362 Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure |
| 03/26/2009 | US20090082360 Use of tyrosine kinase inhibitors for treating CNS disorders |
| 03/26/2009 | US20090082345 Benzothiazole- and benzooxazole-4,7-dione, derivatives and their use as cdc25 phosphate inhibitors |
| 03/26/2009 | US20090082343 1,3-benzothiazinone derivatives and use thereof |
| 03/26/2009 | US20090082307 Culturing Lac Z-Y+ E. coli cell on glycerol and glucose in presence of lactose as exogenous precursor and isopropyl beta -D-thiogalactoside as inducer under conditions inducing the internalization according to a mechanism of active transport of exogenous precursor by cell and production of lactose |
| 03/26/2009 | US20090082298 Methods for producing microRNAs |
| 03/26/2009 | US20090082285 Adiponectin expression promoter |
| 03/26/2009 | US20090082279 Treating a condition associated with breakdown of the blood brain barrier by administering a peptide antagonist of zonulin that binds to the zonula occludens receptor, especially in the brain, yet does not physiologically modulate the opening of mammalian tight junctions |
| 03/26/2009 | US20090082273 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof |
| 03/26/2009 | US20090082267 Prevention and Reduction of Blood Loss |
| 03/26/2009 | US20090082264 123 Human Secreted Proteins |
| 03/26/2009 | US20090082259 Deuterium-enriched octreotide |
| 03/26/2009 | US20090082254 Coupling of Polypeptides at the C-Terminus |
| 03/26/2009 | US20090082223 Method and kit for the determination of cellular activation profiles |
| 03/26/2009 | US20090081780 Canine respiratory coronavirus (crcv) spike protein, polymerase and hemagglutinin/esterase |
| 03/26/2009 | US20090081756 Nucleic acid-enzyme complex |
| 03/26/2009 | US20090081729 Compositions and Methods Comprising a Ligand of ChemerinR |
| 03/26/2009 | US20090081705 Novel peptides and compositions which modulate apoptosis |
| 03/26/2009 | US20090081631 Tissue Engineered Organ |
| 03/26/2009 | US20090081309 Stabilized Oral Suspension Formulation |
| 03/26/2009 | US20090081308 Anhdyrous lactose agglomerates and the preparation thereof |
| 03/26/2009 | US20090081291 Sustained Release Dosage Forms For Delivery of Agents to an Oral Cavity of a User |
| 03/26/2009 | US20090081242 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| 03/26/2009 | US20090081241 comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein |
| 03/26/2009 | US20090081213 Methods and compositions for use in treatment of patients with autoantibody positive disease |
| 03/26/2009 | US20090081190 Methods for Antibody Library Screening |
| 03/26/2009 | US20090081180 Antimicrobial polymer conjugates |
| 03/26/2009 | US20090081179 Method for reducing the severity of neurological disorders |
| 03/26/2009 | US20090081161 Treatment of neoplasms with viruses |
| 03/26/2009 | US20090081160 Method for reducing the likelihood of implantation failure during an assisted reproduction in a subject |
| 03/26/2009 | US20090081123 Pharmaceutical compounds |
| 03/26/2009 | CA2699864A1 Method of treating gaucher disease |
| 03/25/2009 | EP2039779A1 Screening method |
| 03/25/2009 | EP2039768A1 Mutant forms of Fas ligand and uses thereof |
| 03/25/2009 | EP2039700A2 Novel anti-inflammatory androstane derivatives |
| 03/25/2009 | EP2039695A1 Bicyclic heterocyclic compound and use thereof |
| 03/25/2009 | EP2039681A1 Cycloalkene derivatives, process for production of the derivatives, and use of the same |
| 03/25/2009 | EP2039367A1 Prophylactic/therapeutic agent for neurodegenerative disease |
| 03/25/2009 | EP2039357A2 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 03/25/2009 | EP2039356A1 Sialagogue composition comprising a M3 muscarinic agonist and an alpha-2 adrenergic antagonist |
| 03/25/2009 | EP2039354A1 Compound having activity of blocking nmda receptor channel, and pharmaceutical agent using the same |
| 03/25/2009 | EP2038254A2 Bicyclic compositions and methods for modulating a kinase cascade |
| 03/25/2009 | EP2037931A2 Pharmaceutical combinations of pk inhibitors and other active agents |
| 03/25/2009 | EP2037904A1 Basic acetophenones as inhibitors of no-synthases |
| 03/25/2009 | EP2000473A9 Trehalose compound and pharmaceutical comprising the compound |
| 03/25/2009 | EP2000150A9 Titanium oxide complex particle, dispersion solution of the particle, and process for production of the particle |
| 03/25/2009 | EP2000145A9 Ameliorating agent for metabolic syndrome |
| 03/25/2009 | EP1504010B1 Vitamin-mitomycin conjugates |
| 03/25/2009 | EP1472228B1 Process for the manufacture of hmg-coa reductase inhibitors |
| 03/25/2009 | EP1432684B1 Pyridinic sulfonamide derivatives, method of production and use thereof |
| 03/25/2009 | EP1377579B1 Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents |
| 03/25/2009 | EP1353692B1 Methods and compositions for treatment of ocular neovascularization and neural injury |
| 03/25/2009 | EP1299421B1 Antibodies to human mcp-1 |
| 03/25/2009 | EP1287035B1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 03/25/2009 | EP1221847B1 Methods of enhancing chemotherapy |
| 03/25/2009 | EP1053010B1 Copolymer compositions for oral delivery |
| 03/25/2009 | CN101394868A Strong immune induction by using combination of adenovirus type-5/type-35 vector and vaccinia virus mva vector |
| 03/25/2009 | CN101394866A Stabilizer for hydrophobic compounds |
| 03/25/2009 | CN101392026A Polypeptide for preventing and treating fibrotic disease and liver cancer |